drugset / Trial / NCT01079130

Efficacy and Safety of Different Doses of Indacaterol

NCT01079130

Phase 3 Completed 511 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol

Timeline

Start
2010-02
Primary completion
2010-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 18.75 ug Inhaled
Subject Indacaterol Other / unclassified 37.5 ug Inhaled
Subject Indacaterol Other / unclassified 75 ug Inhaled
Subject Indacaterol Other / unclassified 150 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled

Indications